Status:

COMPLETED

Efficacy and Safety Study of XP12B in Women With Menorrhagia

Lead Sponsor:

Ferring Pharmaceuticals

Conditions:

Menorrhagia

Heavy Menstrual Bleeding

Eligibility:

FEMALE

18-49 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.

Eligibility Criteria

Inclusion

  • Women with menorrhagia
  • 18-49 years of age
  • Regularly occurring menstrual periods

Exclusion

  • History or presence of clinically significant disease or abnormalities that may confound the study
  • History of bilateral oophorectomy or hysterectomy
  • Hormone therapy

Key Trial Info

Start Date :

October 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2008

Estimated Enrollment :

196 Patients enrolled

Trial Details

Trial ID

NCT00386308

Start Date

October 1 2006

End Date

May 1 2008

Last Update

May 4 2011

Active Locations (52)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (52 locations)

1

Investigative Site

Tucson, Arizona, United States, 85712

2

Investigative Site

Tucson, Arizona, United States, 85741

3

Investigative Site

Little Rock, Arkansas, United States, 72205

4

Investigative Site

Carmichael, California, United States, 95608

Efficacy and Safety Study of XP12B in Women With Menorrhagia | DecenTrialz